NASDAQ:CLGN - CollPlant Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 57.10 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$16.55
▼ -0.27 (-1.61%)

This chart shows the closing price for CLGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CollPlant Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLGN

Analyst Price Target is $26.00
▲ +57.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CollPlant Biotechnologies in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 57.10% upside from the last price of $16.55.

This chart shows the closing price for CLGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in CollPlant Biotechnologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021HC WainwrightBoost Price TargetBuy$13.00 ➝ $26.00Low
12/2/2020HC WainwrightReiterated RatingBuy$13.00High
5/28/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $13.00High
4/3/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $11.00Low
12/3/2019HC WainwrightReiterated RatingBuy$7.00Low
9/27/2019HC WainwrightSet Price TargetBuy$7.00Low
12/18/2018HC WainwrightInitiated CoverageBuy$7.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
CollPlant Biotechnologies logo
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. It's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $16.55
Low: $16.30
High: $16.82

50 Day Range

MA: $17.59
Low: $16.00
High: $19.47

52 Week Range

Now: $16.55
Low: $6.00
High: $24.26

Volume

6,400 shs

Average Volume

70,686 shs

Market Capitalization

$93.84 million

P/E Ratio

71.96

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CollPlant Biotechnologies?

The following equities research analysts have issued research reports on CollPlant Biotechnologies in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for CLGN.

What is the current price target for CollPlant Biotechnologies?

1 Wall Street analysts have set twelve-month price targets for CollPlant Biotechnologies in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 57.1%. HC Wainwright has the highest price target set, predicting CLGN will reach $26.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $26.00 for CollPlant Biotechnologies in the next year.
View the latest price targets for CLGN.

What is the current consensus analyst rating for CollPlant Biotechnologies?

CollPlant Biotechnologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLGN will outperform the market and that investors should add to their positions of CollPlant Biotechnologies.
View the latest ratings for CLGN.

What other companies compete with CollPlant Biotechnologies?

How do I contact CollPlant Biotechnologies' investor relations team?

CollPlant Biotechnologies' physical mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company's listed phone number is 972732325600 and its investor relations email address is [email protected] The official website for CollPlant Biotechnologies is www.collplant.com.